It's all very interesting. We should also think about why the FDA went with the 6 month review process rather than the 2 month process. In my view the FDA have already made a positive determination. They have gone with a 6 month review because our new BLA contains new data, the new data not only links old with new product and provides a extra level of potency assay that would limit the BLA to a two month review as per guidelines. It must contain what they consider substantial new data supporting efficacy and safety for the BLA to be given the 6 month review.
The data, Emergency usage in adults.
FDA have ruled that this protocol contains substantial new data supporting approval. We have the data for adults. Could a accelerated approval be also given for adults? This would be one way the FDA could be assured a confirmatory trial in adults. Head to head with Rux. in those that have high MAP scores letting those that have already failed 2nd line therapy access to our product.
- Forums
- ASX - By Stock
- MSB
- Cell Therapy News/Articles
Cell Therapy News/Articles, page-17916
-
- There are more pages in this discussion • 157 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
92.0¢ |
Change
-0.020(2.13%) |
Mkt cap ! $1.050B |
Open | High | Low | Value | Volume |
95.0¢ | 95.0¢ | 91.8¢ | $1.818M | 1.964M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 294829 | 92.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
92.5¢ | 5000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 244829 | 0.920 |
15 | 213029 | 0.915 |
16 | 212064 | 0.910 |
5 | 47641 | 0.905 |
34 | 207702 | 0.900 |
Price($) | Vol. | No. |
---|---|---|
0.925 | 5000 | 1 |
0.930 | 67393 | 4 |
0.935 | 82215 | 6 |
0.940 | 52117 | 6 |
0.945 | 79884 | 4 |
Last trade - 16.10pm 16/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |